PolyPid: Advancing D-PLEX100 De-Risks Platform Potential and Creates Compelling Buy-Rated Risk-Reward

In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on PolyPid, with a price target of $13.00.

Brandon Folkes has given his Buy rating due to a combination of factors, chiefly the advancing regulatory path and de-risked commercial outlook for D-PLEX100, which he believes can unlock broader value from PolyPid’s delivery platforms. He points to favorable FDA interactions enabling a rolling NDA submission, active negotiations for a U.S. commercialization deal, and growing validation of localized anti-infective strategies as evidence that D-PLEX100 can secure approval and establish a meaningful market position.

Beyond this lead asset, he views PolyPid as underappreciated for its platform potential, highlighting both the core D-PLEX technology and the newer Kynatrix approach, including an ultra-long-acting GLP-1 program aimed at large metabolic disease markets. Coupled with late-stage clinical data, clearer regulatory visibility, an improving cash runway into the second half of 2026, and the prospect of non-dilutive capital from a potential partnership, he concludes that the current ~$74M valuation presents an appealing risk-reward setup that justifies a Buy rating and a $13 price target.

According to TipRanks, Folkes is a 3-star analyst with an average return of 1.3% and a 40.17% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, Cormedix, and Omeros.